News

Do Race and Ethnicity Play a Role in the Etiology of Liver Cancer?

Unusual Case of Autoimmune Hepatitis Plus Primary Biliary Cholangitis With Atypical Liver Cancer

Cirrhosis and Liver Cancer in West Africa: Focus on Use of Tenofovir Disoproxil Fumarate

How Cholangiocarcinoma Differs in Adolescent and Younger Adults Versus Older Adults

Comparing Thermal Ablation and SBRT for Hepatocellular Carcinoma

Which Patients With Cholangiocarcinoma May Benefit From Perioperative Chemotherapy?

Impact of Tislelizumab Versus Sorafenib on Quality of Life in Hepatocellular Carcinoma

ASCOBT 2023: Novel Strategy for Delivering Immunotherapy Under Study in Liver Cancer

ASCOBT 2023: Investigating Hypoxia-Induced Mechanisms of PD-L1 Inhibitor Resistance in Liver Cancer

Phase III Results Support Novel Combination for Unresectable Hepatocellular Carcinoma

FDA Grants Orphan Drug Designation to Kinase Inhibitor in Treatment of Cholangiocarcinoma

ASCOBT 2023: Does Postoperative Microvascular Invasion Impact Outcomes in Hepatocellular Carcinoma?

Researchers Identify Alterations in Ammonia Metabolic Pathways in Fibrolamellar Liver Cancer

ASCOBT 2023: Can Serum-Based Parameters Predict Outcomes in Unresectable Liver Cancer?

ASCOBT 2023: Is the Gut Microbiome a Key to Predicting Immunotherapy Response in Liver Cancer?

ASCOBT 2023: Study Identifies Potential Therapeutic Target in Gallbladder Cancer

Zanidatamab Immunotherapy for HER2-Positive Advanced Biliary Tract Cancer

Researchers Use Genomics to Inform the Creation of New Model for Pediatric Hepatoblastoma

Can Regular Statin Use Reduce the Risk of Hepatocellular Carcinoma?

Adagrasib Active in Variety of KRAS G12C–Mutated Tumors, Including Biliary Tract Cancer

Trio of Immune Cells Within Tumor Niches May Be Linked to Immunotherapy Response in Liver Cancer

Novel Bispecific Antibody Under Study in Advanced Biliary Tract Cancers

Early Dose-Escalation Data Confirm Potential of FGFR2 Inhibitor in Liver Cancer

ASCO 2023: Adding Sintilimab and Anlotinib to Chemotherapy for Advanced Biliary Tract Cancer

ASCO 2023: Can Neoadjuvant FOLFOX-HAIC Improve Outcomes After Hepatectomy?

ASCO 2023: Identifying Potentially Targetable Gene Mutations in Intrahepatic Cholangiocarcinoma

ASCO 2023: Phase II Trial Assesses Combination Strategies for Treating Gallbladder Adenocarcinoma

ASCO 2023: Quality-of-Life Data With Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer

ASCO 2023: Combination Therapy With Olaparib Plus Pembrolizumab in Biliary Tract Cancers

ASCO 2023: Consolidation Chemoradiotherapy Versus Observation After Chemotherapy for Gallbladder Cancer

ASCO 2023: Zanidatamab Therapy for Refractory HER2-Amplified Biliary Tract Cancer

ASCO 2023: Impact of Immune-Mediated Adverse Events on STRIDE Outcomes in Unresectable Liver Cancer

ASCO 2023: Chemotherapy-Free Regimen for HER2-Positive Metastatic Biliary Tract Cancer

ASCO 2023: Patient-Reported Outcomes With Adjuvant Atezolizumab and Bevacizumab in Hepatocellular Cancer

Timing of Cholangitis and Percutaneous Transhepatic Biliary Drainage

Advanced Biliary Tract Cancer: Is Durvalumab Plus Chemotherapy a Cost-Effective Treatment in China?

Adding Sintilimab to Chemotherapy for Advanced Biliary Tract Cancer

Clinical Practice Guidelines and Real-Life Management of Hepatocellular Carcinoma in Japan

AACR 2023: Microbial Dysbiosis in Extrahepatic Cholangiocarcinoma

AACR 2023: Drug Repositioning and Biomarker Identification in Thai Liver Fluke–Associated Cholangiocarcinoma

AACR 2023: Mechanistic Support for Using CPI-613 in Combination Therapy for Liver Cancer

AACR 2023: Updated Survival Results From Phase II Trial of Pemigatinib in Advanced Cholangiocarcinoma

AACR 2023: Potential Benefits of Combined Anti-CD133 and Anti–PD-L1 in Liver Cancer

AACR 2023: Study Identifies Genetic Marker in Cholangiocarcinoma

AACR 2023: Combination of MET and PD-1 Inhibitors Under Study in Liver Cancer

AACR 2023: Adjuvant Atezolizumab Plus Bevacizumab After Surgery in Liver Cancer

AACR 2023: Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer

NCCN 2023: Updates in the Management of Hepatobiliary Cancers

AACR 2023: Adding Telotristat Ethyl to Standard Chemotherapies for Cholangiocarcinoma

Novel Treatment of Liver Cancer: Photothermal Ablation Therapy Using Gold Nanobipyramids

Surgical Strategies for Intrahepatic Cholangiocarcinoma With Hepatolithiasis

NCCN 2023: Phase II Trial of Futibatinib/Pembrolizumab in Subgroup With Hepatocellular Carcinoma

What Can Be Learned From the Microtubule-Binding Protein HAUS5 in Liver Carcinoma?

Does Postoperative Adjuvant Therapy Improve Outcomes in Cholangiocarcinoma? Chinese Researchers Say Yes